Newswise — A few lucky folks, mostly in Iceland and Scandinavia, carry a mutation that protects them from ever developing Alzheimer’s disease. Discovered five years ago, the mutation reduces the ability of neurons to make toxic amyloid beta (Aβ) peptides, the main ingredient of senile plaques that accumulate in the brain of Alzheimer’s patients. But so far no one had proven that Aβ was actually diminished in people with the mutation. Now, Finnish researchers report for the first time that men carrying the protective gene (called APP A673T) have about one-third less Aβ in their blood than those without the gene. This likely explains why they do not get AD, and raises hopes that, for the vast majority of people without the mutation, drugs now under development that interfere with Aβ synthesis could offer a path to prevention of Alzheimer’s.
Read the full story here.
Founded in 1996, Alzforum is a news and information resource website dedicated to helping researchers accelerate discovery and advance development of diagnostics and treatments for Alzheimer’s disease and related disorders.
Our site expands the traditional mode of scientific communication by reporting the latest scientific findings and industry news with insightful analysis that puts breaking news into context. We advance research by developing open-access databases of curated, highly specific scientific content to visualize and facilitate the exploration of complex data. Alzforum is a platform to disseminate the evolving knowledge around basic, translational, and clinical research in the field of AD.
Alzforum is supported by a team with backgrounds in science, journalism, information technology, design, and data science. Together with a distinguished Scientific Advisory Board, and the active participation of a global network of scientists, we strive to produce unbiased content to a rigorous editorial standard.
Alzforum is operated by the Biomedical Research Forum (BRF) LLC. BRF is a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies. Alzforum does not endorse any specific product or scientific approach.